Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies

{"title":"Bladder-sparing trimodal therapy versus radical cystectomy for muscleinvasive bladder cancer: A systematic review and meta-analysis of comparative studies","authors":"","doi":"10.36879/jcst.20.000115","DOIUrl":null,"url":null,"abstract":"Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or\ntrimodal therapy (TMT).\nMaterials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between\nJune 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy\ncompared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The\nsecondary efficacy endpoints were disease-free survival and local and distant recurrence.\nResults: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates\nfor 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No\nsignificant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status\n(PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and\nlocal and distant recurrence did not differ significantly between the techniques.\nConclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent\nRC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"497 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer science and clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36879/jcst.20.000115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To compare oncologic outcomes between patients with muscle-invasive bladder cancer who were treated with radical cystectomy (RC) or trimodal therapy (TMT). Materials and Methods: The primary sources were the PubMed, Embase, and Cochrane Library electronic databases. Studies published between June 1990 and July 2017 that evaluated combination bladder-sparing surgery for a bladder tumour with radiotherapy (RT) and chemotherapy compared with RC surgery alone for MIBC were included. Published data were extracted and used to calculate the 5-year overall survival rates. The secondary efficacy endpoints were disease-free survival and local and distant recurrence. Results: Nine studies incorporating 15,160 cases were included in the final analysis. Pooled data from 8 studies that assessed overall survival rates for 15,089 patients showed no significant differences in this metric between the TMT and RC groups (HR: 1.27; 95% CI, 0.98-1.63; P=0.066). No significant differences were found between TMT and RC in the subgroup analyses according to the lymph node stage (Nx), age and physiclal status (PS) stage, but differences were found for patients with node-negative disease (HR: 1.36; 95% CI, 1.02-1.81; P=0.036). Disease-free survival and local and distant recurrence did not differ significantly between the techniques. Conclusion: RC seems to be suitable for node-negative disease patients. TMT yielded survival outcomes similar to those of patients who underwent RC. Given the inherent limitations of the included studies, future well-designed RCTs are needed to confirm and update the findings of this analysis.
肌肉浸润性膀胱癌保留膀胱三模式治疗与根治性膀胱切除术:比较研究的系统回顾和荟萃分析
目的:比较肌肉浸润性膀胱癌患者行根治性膀胱切除术(RC)和三模治疗(TMT)的肿瘤预后。材料和方法:主要来源是PubMed、Embase和Cochrane图书馆的电子数据库。1990年6月至2017年7月期间发表的研究评估了膀胱肿瘤联合放疗(RT)和化疗的保膀胱手术与单独RC手术治疗MIBC的比较。提取已发表的数据并用于计算5年总生存率。次要疗效终点为无病生存期、局部和远处复发。结果:9项研究纳入15160例最终分析。来自8项研究的汇总数据评估了15089例患者的总生存率,结果显示TMT组和RC组在这一指标上没有显著差异(HR: 1.27;95% ci, 0.98-1.63;P = 0.066)。根据淋巴结分期(Nx)、年龄和身体状况(PS)分期的亚组分析,TMT和RC之间无显著差异,但在淋巴结阴性疾病患者中存在差异(HR: 1.36;95% ci, 1.02-1.81;P = 0.036)。无病生存率和局部和远处复发在两种技术之间没有显著差异。结论:RC似乎适用于淋巴结阴性患者。TMT产生的生存结果与接受entrc的患者相似。考虑到纳入研究的固有局限性,需要未来设计良好的随机对照试验来确认和更新本分析的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信